Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

SLC1A3 contributes to L-asparaginase resistance in solid tumors.

Sun J, Nagel R, Zaal EA, Ugalde AP, Han R, Proost N, Song JY, Pataskar A, Burylo A, Fu H, Poelarends GJ, van de Ven M, van Tellingen O, Berkers CR, Agami R.

EMBO J. 2019 Sep 16:e102147. doi: 10.15252/embj.2019102147. [Epub ahead of print]

2.

A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation.

Korkmaz G, Manber Z, Lopes R, Prekovic S, Schuurman K, Kim Y, Teunissen H, Flach K, Wit E, Galli GG, Zwart W, Elkon R, Agami R.

Nucleic Acids Res. 2019 Oct 10;47(18):9557-9572. doi: 10.1093/nar/gkz675.

3.

A fragment-like approach to PYCR1 inhibition.

Milne K, Sun J, Zaal EA, Mowat J, Celie PHN, Fish A, Berkers CR, Forlani G, Loayza-Puch F, Jamieson C, Agami R.

Bioorg Med Chem Lett. 2019 Sep 15;29(18):2626-2631. doi: 10.1016/j.bmcl.2019.07.047. Epub 2019 Jul 25.

PMID:
31362921
4.

Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells.

Kampen KR, Fancello L, Girardi T, Rinaldi G, Planque M, Sulima SO, Loayza-Puch F, Verbelen B, Vereecke S, Verbeeck J, Op de Beeck J, Royaert J, Vermeersch P, Cassiman D, Cools J, Agami R, Fiers M, Fendt SM, De Keersmaecker K.

Nat Commun. 2019 Jun 11;10(1):2542. doi: 10.1038/s41467-019-10508-2.

5.

SCAF4 and SCAF8, mRNA Anti-Terminator Proteins.

Gregersen LH, Mitter R, Ugalde AP, Nojima T, Proudfoot NJ, Agami R, Stewart A, Svejstrup JQ.

Cell. 2019 Jun 13;177(7):1797-1813.e18. doi: 10.1016/j.cell.2019.04.038. Epub 2019 May 16.

6.

Queuing up the ribosome: nutrition and the microbiome control protein synthesis.

Kozlovski I, Agami R.

EMBO J. 2018 Sep 14;37(18). pii: e100405. doi: 10.15252/embj.2018100405. Epub 2018 Sep 3.

7.

CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells.

Lopes R, Korkmaz G, Revilla SA, van Vliet R, Nagel R, Custers L, Kim Y, van Breugel PC, Zwart W, Moumbeini B, Manber Z, Elkon R, Agami R.

Cancer Lett. 2018 Nov 1;436:87-95. doi: 10.1016/j.canlet.2018.08.018. Epub 2018 Aug 23.

8.

Functional CRISPR screen identifies AP1-associated enhancer regulating FOXF1 to modulate oncogene-induced senescence.

Han R, Li L, Ugalde AP, Tal A, Manber Z, Barbera EP, Chiara VD, Elkon R, Agami R.

Genome Biol. 2018 Aug 17;19(1):118. doi: 10.1186/s13059-018-1494-1.

9.

FcαRI co-stimulation converts human intestinal CD103+ dendritic cells into pro-inflammatory cells through glycolytic reprogramming.

Hansen IS, Krabbendam L, Bernink JH, Loayza-Puch F, Hoepel W, van Burgsteden JA, Kuijper EC, Buskens CJ, Bemelman WA, Zaat SAJ, Agami R, Vidarsson G, van den Brink GR, de Jong EC, Wildenberg ME, Baeten DLP, Everts B, den Dunnen J.

Nat Commun. 2018 Feb 28;9(1):863. doi: 10.1038/s41467-018-03318-5.

10.

LncRNA-OIS1 regulates DPP4 activation to modulate senescence induced by RAS.

Li L, van Breugel PC, Loayza-Puch F, Ugalde AP, Korkmaz G, Messika-Gold N, Han R, Lopes R, Barbera EP, Teunissen H, de Wit E, Soares RJ, Nielsen BS, Holmstrøm K, Martínez-Herrera DJ, Huarte M, Louloupi A, Drost J, Elkon R, Agami R.

Nucleic Acids Res. 2018 May 4;46(8):4213-4227. doi: 10.1093/nar/gky087.

11.

Using mitoribosomal profiling to investigate human mitochondrial translation.

Gao F, Wesolowska M, Agami R, Rooijers K, Loayza-Puch F, Lawless C, Lightowlers RN, Chrzanowska-Lightowlers ZMA.

Wellcome Open Res. 2017 Dec 11;2:116. doi: 10.12688/wellcomeopenres.13119.2. eCollection 2017.

12.

Nuclear poly(A)-binding protein 1 is an ATM target and essential for DNA double-strand break repair.

Gavish-Izakson M, Velpula BB, Elkon R, Prados-Carvajal R, Barnabas GD, Ugalde AP, Agami R, Geiger T, Huertas P, Ziv Y, Shiloh Y.

Nucleic Acids Res. 2018 Jan 25;46(2):730-747. doi: 10.1093/nar/gkx1240.

13.

Long non-coding RNAs in metastasis.

Huang Q, Yan J, Agami R.

Cancer Metastasis Rev. 2018 Mar;37(1):75-81. doi: 10.1007/s10555-017-9713-x. Review.

PMID:
29230620
14.

The methylated way to translation.

Han R, Slobodin B, Agami R.

Oncotarget. 2017 Oct 25;8(55):93313-93314. doi: 10.18632/oncotarget.22073. eCollection 2017 Nov 7. No abstract available.

15.

Characterization of noncoding regulatory DNA in the human genome.

Elkon R, Agami R.

Nat Biotechnol. 2017 Aug 8;35(8):732-746. doi: 10.1038/nbt.3863. Review.

PMID:
28787426
16.

Transcription Impacts the Efficiency of mRNA Translation via Co-transcriptional N6-adenosine Methylation.

Slobodin B, Han R, Calderone V, Vrielink JAFO, Loayza-Puch F, Elkon R, Agami R.

Cell. 2017 Apr 6;169(2):326-337.e12. doi: 10.1016/j.cell.2017.03.031.

17.

GRO-seq, A Tool for Identification of Transcripts Regulating Gene Expression.

Lopes R, Agami R, Korkmaz G.

Methods Mol Biol. 2017;1543:45-55. doi: 10.1007/978-1-4939-6716-2_3.

PMID:
28349421
18.

TGFβ1-induced leucine limitation uncovered by differential ribosome codon reading.

Loayza-Puch F, Rooijers K, Zijlstra J, Moumbeini B, Zaal EA, Oude Vrielink JF, Lopes R, Ugalde AP, Berkers CR, Agami R.

EMBO Rep. 2017 Apr;18(4):549-557. doi: 10.15252/embr.201744000. Epub 2017 Mar 8.

19.

microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network.

Zhou Y, Frings O, Branca RM, Boekel J, le Sage C, Fredlund E, Agami R, Orre LM.

Oncogene. 2017 Feb 9;36(6):731-745. doi: 10.1038/onc.2016.242. Epub 2016 Aug 1.

20.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.

J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

21.

Applying CRISPR-Cas9 tools to identify and characterize transcriptional enhancers.

Lopes R, Korkmaz G, Agami R.

Nat Rev Mol Cell Biol. 2016 Sep;17(9):597-604. doi: 10.1038/nrm.2016.79. Epub 2016 Jul 6.

PMID:
27381243
22.

Monitoring amino acid deficiencies in cancer.

Loayza-Puch F, Agami R.

Cell Cycle. 2016 Sep;15(17):2229-30. doi: 10.1080/15384101.2016.1191256. Epub 2016 May 31. No abstract available.

23.

3'UTR Shortening Potentiates MicroRNA-Based Repression of Pro-differentiation Genes in Proliferating Human Cells.

Hoffman Y, Bublik DR, Ugalde AP, Elkon R, Biniashvili T, Agami R, Oren M, Pilpel Y.

PLoS Genet. 2016 Feb 23;12(2):e1005879. doi: 10.1371/journal.pgen.1005879. eCollection 2016 Feb. Erratum in: PLoS Genet. 2016 Aug;12(8):e1006254.

24.

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

Loayza-Puch F, Rooijers K, Buil LC, Zijlstra J, Oude Vrielink JF, Lopes R, Ugalde AP, van Breugel P, Hofland I, Wesseling J, van Tellingen O, Bex A, Agami R.

Nature. 2016 Feb 25;530(7591):490-4. doi: 10.1038/nature16982. Epub 2016 Feb 15.

PMID:
26878238
25.

A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response.

Melo CA, Léveillé N, Rooijers K, Wijchers PJ, Geeven G, Tal A, Melo SA, de Laat W, Agami R.

Oncogene. 2016 Aug 18;35(33):4399-406. doi: 10.1038/onc.2015.502. Epub 2016 Jan 18.

PMID:
26776159
26.

Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9.

Korkmaz G, Lopes R, Ugalde AP, Nevedomskaya E, Han R, Myacheva K, Zwart W, Elkon R, Agami R.

Nat Biotechnol. 2016 Feb;34(2):192-8. doi: 10.1038/nbt.3450. Epub 2016 Jan 11.

PMID:
26751173
27.

Genome-Wide Polyadenylation Maps Reveal Dynamic mRNA 3'-End Formation in the Failing Human Heart.

Creemers EE, Bawazeer A, Ugalde AP, van Deutekom HW, van der Made I, de Groot NE, Adriaens ME, Cook SA, Bezzina CR, Hubner N, van der Velden J, Elkon R, Agami R, Pinto YM.

Circ Res. 2016 Feb 5;118(3):433-8. doi: 10.1161/CIRCRESAHA.115.307082. Epub 2015 Dec 15. Erratum in: Circ Res. 2016 Oct 14;119(9):e139.

PMID:
26671978
28.

Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.

Elkon R, Loayza-Puch F, Korkmaz G, Lopes R, van Breugel PC, Bleijerveld OB, Altelaar AF, Wolf E, Lorenzin F, Eilers M, Agami R.

EMBO Rep. 2015 Dec;16(12):1723-36. doi: 10.15252/embr.201540717. Epub 2015 Nov 4.

29.

Exposure to arginine analog canavanine induces aberrant mitochondrial translation products, mitoribosome stalling, and instability of the mitochondrial proteome.

Konovalova S, Hilander T, Loayza-Puch F, Rooijers K, Agami R, Tyynismaa H.

Int J Biochem Cell Biol. 2015 Aug;65:268-74. doi: 10.1016/j.biocel.2015.06.018. Epub 2015 Jun 25.

PMID:
26117454
30.

Enhancer-associated RNAs as therapeutic targets.

Léveillé N, Melo CA, Agami R.

Expert Opin Biol Ther. 2015 May;15(5):723-34. doi: 10.1517/14712598.2015.1029452. Epub 2015 Mar 29. Review.

PMID:
25819025
31.

Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA.

Léveillé N, Melo CA, Rooijers K, Díaz-Lagares A, Melo SA, Korkmaz G, Lopes R, Moqadam FA, Maia AR, Wijchers PJ, Geeven G, den Boer ML, Kalluri R, de Laat W, Esteller M, Agami R.

Nat Commun. 2015 Mar 27;6:6520. doi: 10.1038/ncomms7520.

32.

Transcription initiation determines its end.

Slobodin B, Agami R.

Mol Cell. 2015 Jan 22;57(2):205-6. doi: 10.1016/j.molcel.2015.01.006.

33.

miR-155 drives telomere fragility in human breast cancer by targeting TRF1.

Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S.

Cancer Res. 2014 Aug 1;74(15):4145-56. doi: 10.1158/0008-5472.CAN-13-2038. Epub 2014 May 29.

34.

Ribosome profiling reveals features of normal and disease-associated mitochondrial translation.

Rooijers K, Loayza-Puch F, Nijtmans LG, Agami R.

Nat Commun. 2013;4:2886. doi: 10.1038/ncomms3886.

35.

Lncing protein translation to metastasis.

Loayza-Puch F, Agami R.

EMBO J. 2013 Oct 16;32(20):2657-8. doi: 10.1038/emboj.2013.210. Epub 2013 Sep 24. No abstract available.

36.

Identification of lethal microRNAs specific for head and neck cancer.

Lindenbergh-van der Plas M, Martens-de Kemp SR, de Maaker M, van Wieringen WN, Ylstra B, Agami R, Cerisoli F, Leemans CR, Braakhuis BJ, Brakenhoff RH.

Clin Cancer Res. 2013 Oct 15;19(20):5647-57. doi: 10.1158/1078-0432.CCR-12-2295. Epub 2013 Aug 13.

37.

eRNAs reach the heart of transcription.

Melo CA, Léveillé N, Agami R.

Cell Res. 2013 Oct;23(10):1151-2. doi: 10.1038/cr.2013.97. Epub 2013 Jul 23.

38.

A versatile microsatellite instability reporter system in human cells.

Koole W, Schäfer HS, Agami R, van Haaften G, Tijsterman M.

Nucleic Acids Res. 2013 Sep;41(16):e158. doi: 10.1093/nar/gkt615. Epub 2013 Jul 16.

39.

Noncoding RNAs and cancer.

Lieberman J, Slack F, Pandolfi PP, Chinnaiyan A, Agami R, Mendell JT.

Cell. 2013 Mar 28;153(1):9-10. No abstract available.

40.

Alternative cleavage and polyadenylation: extent, regulation and function.

Elkon R, Ugalde AP, Agami R.

Nat Rev Genet. 2013 Jul;14(7):496-506. doi: 10.1038/nrg3482. Review.

PMID:
23774734
41.

Exogenous treatment with indole-3-acetic acid and salicylic acid alleviates cadmium toxicity in wheat seedlings.

Agami RA, Mohamed GF.

Ecotoxicol Environ Saf. 2013 Aug;94:164-71. doi: 10.1016/j.ecoenv.2013.04.013. Epub 2013 May 17.

PMID:
23684274
42.

Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.

Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G.

Cell Cycle. 2013 Jun 1;12(11):1679-87. doi: 10.4161/cc.24757. Epub 2013 May 1.

43.

p53 induces transcriptional and translational programs to suppress cell proliferation and growth.

Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R, Agami R.

Genome Biol. 2013 Apr 17;14(4):R32. doi: 10.1186/gb-2013-14-4-r32.

44.

Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis.

Wilting SM, Verlaat W, Jaspers A, Makazaji NA, Agami R, Meijer CJ, Snijders PJ, Steenbergen RD.

Epigenetics. 2013 Feb;8(2):220-8. doi: 10.4161/epi.23605. Epub 2013 Jan 16.

45.

MIR181A regulates starvation- and rapamycin-induced autophagy through targeting of ATG5.

Tekirdag KA, Korkmaz G, Ozturk DG, Agami R, Gozuacik D.

Autophagy. 2013 Mar;9(3):374-85. doi: 10.4161/auto.23117. Epub 2013 Jan 15.

46.

eRNAs are required for p53-dependent enhancer activity and gene transcription.

Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JA, Elkon R, Melo SA, Léveillé N, Kalluri R, de Laat W, Agami R.

Mol Cell. 2013 Feb 7;49(3):524-35. doi: 10.1016/j.molcel.2012.11.021. Epub 2012 Dec 27.

47.

Alternative cleavage and polyadenylation during colorectal cancer development.

Morris AR, Bos A, Diosdado B, Rooijers K, Elkon R, Bolijn AS, Carvalho B, Meijer GA, Agami R.

Clin Cancer Res. 2012 Oct 1;18(19):5256-66. doi: 10.1158/1078-0432.CCR-12-0543. Epub 2012 Aug 8.

48.

E2F mediates enhanced alternative polyadenylation in proliferation.

Elkon R, Drost J, van Haaften G, Jenal M, Schrier M, Oude Vrielink JA, Agami R.

Genome Biol. 2012 Jul 2;13(7):R59. doi: 10.1186/gb-2012-13-7-r59.

49.

The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites.

Jenal M, Elkon R, Loayza-Puch F, van Haaften G, Kühn U, Menzies FM, Oude Vrielink JA, Bos AJ, Drost J, Rooijers K, Rubinsztein DC, Agami R.

Cell. 2012 Apr 27;149(3):538-53. doi: 10.1016/j.cell.2012.03.022. Epub 2012 Apr 12.

50.

Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis.

Wilting SM, Snijders PJ, Verlaat W, Jaspers A, van de Wiel MA, van Wieringen WN, Meijer GA, Kenter GG, Yi Y, le Sage C, Agami R, Meijer CJ, Steenbergen RD.

Oncogene. 2013 Jan 3;32(1):106-16. doi: 10.1038/onc.2012.20. Epub 2012 Feb 13.

PMID:
22330141

Supplemental Content

Support Center